A Research Viewpoint.
Oligovax is a biopharmaceutical company focused on developing innovative therapies for cancer.
The company’s leads molecule, Litenimod, is potent agonist of toll Like receptor 9 (TLR9), triggering both innate and adaptive immune response.
Such a mechanism of action provides the potential to use Litenimod either alone, or as a vaccine adjuvant, or combined to monocolonal antibodies.
Oligovax has successfully completed several clinical trials in cancer, and is conducting pre-clinical studies using Litenimod as an adjuvant in vaccine and/or immunotherapeutic approaches.
Creating places that enhance the human experience.
Useful options
Beautiful snippets
Amazing pages
Building Castle in Cloud
When designing an architectural concept, we take into account the nine criteria that Zumthor considers to be important in creating an architectural atmosphere.
